CHMP Favors At-home Injection Form of Remsima for Europe

The Committee for Medicinal Products for Human Use (CHMP), a branch of the European Medicines Agency (EMA), is recommending the use of a subcutaneous (under the skin) injection formulation of Remsima (infliximab) by people with ankylosing spondylitis and four other disorders. Celltrion Healthcare designed this new version…

CHMP Recommends Enbrel Biosimilar Nepexto for Approval in Europe

The Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Nepexto, a biosimilar of Enbrel (etanercept), for the treatment of various inflammatory disorders including ankylosing spondylitis. CHMP is an arm of the European Medicines Agency. and the European Commission generally accepts opinions released…